Optimization of shRNA inhibitors by variation of the terminal loop sequence
Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity o...
Gespeichert in:
Veröffentlicht in: | Antiviral research 2010-05, Vol.86 (2), p.204-211 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 211 |
---|---|
container_issue | 2 |
container_start_page | 204 |
container_title | Antiviral research |
container_volume | 86 |
creator | Schopman, Nick C.T. Liu, Ying Poi Konstantinova, Pavlina ter Brake, Olivier Berkhout, Ben |
description | Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity of corresponding synthetic siRNAs that attack the same target sequence. One obvious difference between these two effector molecules is the hairpin loop of the shRNA. Most studies use the original shRNA design of the pSuper system, but no extensive study regarding optimization of the shRNA loop sequence has been performed. We tested the impact of different hairpin loop sequences, varying in size and structure, on the activity of a set of shRNAs targeting HIV-1. We were able to transform weak inhibitors into intermediate or even strong shRNA inhibitors by replacing the loop sequence. We demonstrate that the efficacy of these optimized shRNA inhibitors is improved significantly in different cell types due to increased siRNA production. These results indicate that the loop sequence is an essential part of the shRNA design. The optimized shRNA loop sequence is generally applicable for RNAi knockdown studies, and will allow us to develop a more potent gene therapy against HIV-1. |
doi_str_mv | 10.1016/j.antiviral.2010.02.320 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877570378</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354210003797</els_id><sourcerecordid>733300796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-e21ddc18584caa481ca1f7e2c11aba64f387299ed0cd26df4c7125044ce311263</originalsourceid><addsrcrecordid>eNqFkEtrGzEURkVpSZy0f6GdTclqXL1G0ixNyIuEBkq7FrLmDr5mZuRKsiH99ZGx4y6zunA5330cQr4xOmeUqR_ruZsy7jC6Yc5p6VI-F5x-IDNmNK9b2qqPZFZIVYtG8nNykdKaUqp0a87IeYkYo5WckcfnTcYR_7mMYapCX6XVr5-LCqcVLjGHmKrlS7VzEU9AXkGVIY44uaEaQthUCf5uYfLwmXzq3ZDgy7Fekj-3N7-v7-un57uH68VT7aXguQbOus4z0xjpnZOGecd6Ddwz5pZOyV6UF9oWOuo7rrpees14Q6X0IBjjSlySq8PcTQxlc8p2xORhGNwEYZus0brRVGjzLqmFEJTqdj9TH0gfQ0oReruJOLr4Yhm1e-V2bU_K7V65pdwW5SX59bhjuxyhO-XeHBfg-xFwybuhj27ymP5zXJlGNG3hFgcOirsdQrTJ495rhxF8tl3Ad495BfG5o4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733300796</pqid></control><display><type>article</type><title>Optimization of shRNA inhibitors by variation of the terminal loop sequence</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Schopman, Nick C.T. ; Liu, Ying Poi ; Konstantinova, Pavlina ; ter Brake, Olivier ; Berkhout, Ben</creator><creatorcontrib>Schopman, Nick C.T. ; Liu, Ying Poi ; Konstantinova, Pavlina ; ter Brake, Olivier ; Berkhout, Ben</creatorcontrib><description>Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity of corresponding synthetic siRNAs that attack the same target sequence. One obvious difference between these two effector molecules is the hairpin loop of the shRNA. Most studies use the original shRNA design of the pSuper system, but no extensive study regarding optimization of the shRNA loop sequence has been performed. We tested the impact of different hairpin loop sequences, varying in size and structure, on the activity of a set of shRNAs targeting HIV-1. We were able to transform weak inhibitors into intermediate or even strong shRNA inhibitors by replacing the loop sequence. We demonstrate that the efficacy of these optimized shRNA inhibitors is improved significantly in different cell types due to increased siRNA production. These results indicate that the loop sequence is an essential part of the shRNA design. The optimized shRNA loop sequence is generally applicable for RNAi knockdown studies, and will allow us to develop a more potent gene therapy against HIV-1.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2010.02.320</identifier><identifier>PMID: 20188764</identifier><identifier>CODEN: ARSRDR</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - pharmacology ; Biological and medical sciences ; Biological Products - genetics ; Biological Products - pharmacology ; Cell Line ; Cercopithecus aethiops ; Gene Knockdown Techniques - methods ; Gene Silencing ; Hairpin loop ; HIV-1 - drug effects ; HIV-1 replication ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Medical sciences ; Pharmacology. Drug treatments ; RNA, Small Interfering - genetics ; RNA, Small Interfering - pharmacology ; shRNA ; siRNA ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virus Replication - drug effects</subject><ispartof>Antiviral research, 2010-05, Vol.86 (2), p.204-211</ispartof><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-e21ddc18584caa481ca1f7e2c11aba64f387299ed0cd26df4c7125044ce311263</citedby><cites>FETCH-LOGICAL-c432t-e21ddc18584caa481ca1f7e2c11aba64f387299ed0cd26df4c7125044ce311263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0166354210003797$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22685359$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20188764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schopman, Nick C.T.</creatorcontrib><creatorcontrib>Liu, Ying Poi</creatorcontrib><creatorcontrib>Konstantinova, Pavlina</creatorcontrib><creatorcontrib>ter Brake, Olivier</creatorcontrib><creatorcontrib>Berkhout, Ben</creatorcontrib><title>Optimization of shRNA inhibitors by variation of the terminal loop sequence</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity of corresponding synthetic siRNAs that attack the same target sequence. One obvious difference between these two effector molecules is the hairpin loop of the shRNA. Most studies use the original shRNA design of the pSuper system, but no extensive study regarding optimization of the shRNA loop sequence has been performed. We tested the impact of different hairpin loop sequences, varying in size and structure, on the activity of a set of shRNAs targeting HIV-1. We were able to transform weak inhibitors into intermediate or even strong shRNA inhibitors by replacing the loop sequence. We demonstrate that the efficacy of these optimized shRNA inhibitors is improved significantly in different cell types due to increased siRNA production. These results indicate that the loop sequence is an essential part of the shRNA design. The optimized shRNA loop sequence is generally applicable for RNAi knockdown studies, and will allow us to develop a more potent gene therapy against HIV-1.</description><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Biological Products - genetics</subject><subject>Biological Products - pharmacology</subject><subject>Cell Line</subject><subject>Cercopithecus aethiops</subject><subject>Gene Knockdown Techniques - methods</subject><subject>Gene Silencing</subject><subject>Hairpin loop</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 replication</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>RNA, Small Interfering - genetics</subject><subject>RNA, Small Interfering - pharmacology</subject><subject>shRNA</subject><subject>siRNA</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Virus Replication - drug effects</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtrGzEURkVpSZy0f6GdTclqXL1G0ixNyIuEBkq7FrLmDr5mZuRKsiH99ZGx4y6zunA5330cQr4xOmeUqR_ruZsy7jC6Yc5p6VI-F5x-IDNmNK9b2qqPZFZIVYtG8nNykdKaUqp0a87IeYkYo5WckcfnTcYR_7mMYapCX6XVr5-LCqcVLjGHmKrlS7VzEU9AXkGVIY44uaEaQthUCf5uYfLwmXzq3ZDgy7Fekj-3N7-v7-un57uH68VT7aXguQbOus4z0xjpnZOGecd6Ddwz5pZOyV6UF9oWOuo7rrpees14Q6X0IBjjSlySq8PcTQxlc8p2xORhGNwEYZus0brRVGjzLqmFEJTqdj9TH0gfQ0oReruJOLr4Yhm1e-V2bU_K7V65pdwW5SX59bhjuxyhO-XeHBfg-xFwybuhj27ymP5zXJlGNG3hFgcOirsdQrTJ495rhxF8tl3Ad495BfG5o4g</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Schopman, Nick C.T.</creator><creator>Liu, Ying Poi</creator><creator>Konstantinova, Pavlina</creator><creator>ter Brake, Olivier</creator><creator>Berkhout, Ben</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20100501</creationdate><title>Optimization of shRNA inhibitors by variation of the terminal loop sequence</title><author>Schopman, Nick C.T. ; Liu, Ying Poi ; Konstantinova, Pavlina ; ter Brake, Olivier ; Berkhout, Ben</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-e21ddc18584caa481ca1f7e2c11aba64f387299ed0cd26df4c7125044ce311263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Biological Products - genetics</topic><topic>Biological Products - pharmacology</topic><topic>Cell Line</topic><topic>Cercopithecus aethiops</topic><topic>Gene Knockdown Techniques - methods</topic><topic>Gene Silencing</topic><topic>Hairpin loop</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 replication</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>RNA, Small Interfering - genetics</topic><topic>RNA, Small Interfering - pharmacology</topic><topic>shRNA</topic><topic>siRNA</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schopman, Nick C.T.</creatorcontrib><creatorcontrib>Liu, Ying Poi</creatorcontrib><creatorcontrib>Konstantinova, Pavlina</creatorcontrib><creatorcontrib>ter Brake, Olivier</creatorcontrib><creatorcontrib>Berkhout, Ben</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schopman, Nick C.T.</au><au>Liu, Ying Poi</au><au>Konstantinova, Pavlina</au><au>ter Brake, Olivier</au><au>Berkhout, Ben</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of shRNA inhibitors by variation of the terminal loop sequence</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>86</volume><issue>2</issue><spage>204</spage><epage>211</epage><pages>204-211</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><coden>ARSRDR</coden><abstract>Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity of corresponding synthetic siRNAs that attack the same target sequence. One obvious difference between these two effector molecules is the hairpin loop of the shRNA. Most studies use the original shRNA design of the pSuper system, but no extensive study regarding optimization of the shRNA loop sequence has been performed. We tested the impact of different hairpin loop sequences, varying in size and structure, on the activity of a set of shRNAs targeting HIV-1. We were able to transform weak inhibitors into intermediate or even strong shRNA inhibitors by replacing the loop sequence. We demonstrate that the efficacy of these optimized shRNA inhibitors is improved significantly in different cell types due to increased siRNA production. These results indicate that the loop sequence is an essential part of the shRNA design. The optimized shRNA loop sequence is generally applicable for RNAi knockdown studies, and will allow us to develop a more potent gene therapy against HIV-1.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>20188764</pmid><doi>10.1016/j.antiviral.2010.02.320</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0166-3542 |
ispartof | Antiviral research, 2010-05, Vol.86 (2), p.204-211 |
issn | 0166-3542 1872-9096 |
language | eng |
recordid | cdi_proquest_miscellaneous_877570378 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - pharmacology Biological and medical sciences Biological Products - genetics Biological Products - pharmacology Cell Line Cercopithecus aethiops Gene Knockdown Techniques - methods Gene Silencing Hairpin loop HIV-1 - drug effects HIV-1 replication Human immunodeficiency virus 1 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Medical sciences Pharmacology. Drug treatments RNA, Small Interfering - genetics RNA, Small Interfering - pharmacology shRNA siRNA Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Virus Replication - drug effects |
title | Optimization of shRNA inhibitors by variation of the terminal loop sequence |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A53%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20shRNA%20inhibitors%20by%20variation%20of%20the%20terminal%20loop%20sequence&rft.jtitle=Antiviral%20research&rft.au=Schopman,%20Nick%20C.T.&rft.date=2010-05-01&rft.volume=86&rft.issue=2&rft.spage=204&rft.epage=211&rft.pages=204-211&rft.issn=0166-3542&rft.eissn=1872-9096&rft.coden=ARSRDR&rft_id=info:doi/10.1016/j.antiviral.2010.02.320&rft_dat=%3Cproquest_cross%3E733300796%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733300796&rft_id=info:pmid/20188764&rft_els_id=S0166354210003797&rfr_iscdi=true |